Affiliation:
1. Department of Otolaryngology – Head & Neck Surgery National University Hospital Singapore Singapore
2. Department of Pathology National University Hospital Singapore Singapore
3. Department of Otolaryngology Yong Loo Lin School of Medicine, National University of Singapore Singapore Singapore
4. Department of Otolaryngology – Head & Neck Surgery Ng Teng Fong General Hospital Singapore Singapore
Abstract
AbstractBackgroundSWI/SNF complex‐deficient sinonasal carcinomas are rare, genetically distinct, and aggressive entities.MethodsSMARCB1 and SMARCA4 immunohistochemistry was retrospectively performed on a cohort of undifferentiated, poorly differentiated, and poorly defined sinonasal carcinomas. Survival outcomes were compared between SMARCB1/SMARCA4 (SWI/SNF complex)‐deficient and ‐retained groups.ResultsEight SWI/SNF complex‐deficient (six SMARCB1‐deficient, two SMARCA4‐deficient) cases were identified among 47 patients over 12 years. Triple‐modality treatment was more frequently utilized in SWI/SNF complex‐deficient carcinomas than in SWI/SNF complex‐retained carcinomas (71.4% vs. 11.8%, p = 0.001). After a median follow‐up of 21.3 (IQR 9.9–56.0) months, SWI/SNF complex‐deficient sinonasal carcinomas showed comparable recurrence rates (57.1% vs. 52.9%, p = 0.839), time‐to‐recurrence (7.3 [IQR 6.6–8.3] vs. 9.1 [IQR 3.9–17.4] months, p = 0.531), and overall survival (17.7 [IQR 11.8–67.0] vs. 21.6 [IQR 8.9–56.0] months, p = 0.835) compared to SWI/SNF complex‐retained sinonasal carcinomas.ConclusionTriple‐modality treatment may improve survival in SWI/SNF complex‐deficient sinonasal carcinomas.